Cumberland Pharmaceuticals Inc.
CPIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company carries a $101.7M market cap, placing it firmly in the micro-cap category. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Market Cap
$101.7M
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
48.50
EPS (TTM)
$-0.22
EPS (Fwd)
$0.14
ROE
-14.4%
ROA
-2.9%
Cash
$3.9M
Total Debt
$4.7M
Free CF
-$191,169
52W Change
99.7%
Annual Financials
Cash vs Debt
Where CPIX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CPIX finished 51.63% above its 150-day moving average ($4.30) and 67.61% above its 200-day moving average ($3.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CPIX overbought or oversold?
At the September 3, 2026 close, CPIX's RSI(14) was 34.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CPIX has $3.9M in cash with $4.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$191K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -14.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $42.0M (2022) to $44.5M (2025).
The relatively low beta of 0.10 suggests CPIX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CPIX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.